Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata without access to the full letter text, the FDA issued a Warning Letter to Lattice Biologics, Ltd., a company manufacturing biologic products, on August 27, 2020. Without the specific subject line details, the exact nature of the violations cannot be determined from the available information. The warning was issued under the FDA's biologics regulatory authority, which typically oversees manufacturing, quality control, and compliance issues for biological drug products. To understand the specific violations and required corrective actions, the complete Warning Letter document would need to be reviewed.